Abstract:The increasing focus on patient centricity in the pharmaceutical industry over the past decade and the changing healthcare landscape, driven by factors such as increased access to information, social media, and evolving patient demands, has necessitated a shift toward greater connectivity and understanding of patients' unique treatment needs. One pharmaceutical technology that has supported these efforts is long acting injectables (LAIs), which lower the administration frequency for the patient's provided convenience, better compliance, and hence better therapeutical treatment for the patients. Furthermore, patients with conditions like the human immunodeficiency virus and schizophrenia have positively expressed the desire for less frequent dosing, such as that obtained through LAI formulations. In this work, a comprehensive analysis of marketed LAIs across therapeutic classes and technologies is conducted. The analysis demonstrated an increasing number of new LAIs being brought to the market, recently most as aqueous suspensions and one as a solution, but many other technology platforms were applied as well, in particular, polymeric microspheres and in situ forming gels. The analysis across the technologies provided an insight into to the physicochemical properties the compounds had per technology class as well as knowledge of the excipients typically used within the individual formulation technology. The principle behind the formulation technologies was discussed with respect to the release mechanism, manufacturing approaches, and the possibility of defining predictive in vitro release methods to obtain in vitro in vivo correlations with an industrial angle. The gaps in the field are still numerous, including better systematic formulation and manufacturing investigations to get a better understanding of potential innovations, but also development of new polymers could facilitate the development of additional compounds. The biggest and most important gaps, however, seem to be the development of predictive in vitro dissolution methods utilizing pharmacopoeia described equipment to enable their use for product development and later in the product cycle for quality-based purposes.

Drugs for Long Acting Injections and Implants

Injectable controlled release depots for large molecules

An in situ-forming, solid lipid/PLGA hybrid implant for long-acting antipsychotics

Injectable long-acting formulations (ILAFs) and manufacturing techniques

Long-acting injectable formulation technologies: challenges and opportunities for the delivery of fragile molecules

Long acting injectable formulations: the state of the arts and challenges of poly(lactic-co-glycolic acid) microsphere, hydrogel, organogel and liquid crystal

Clinical translation of long-acting drug delivery formulations

The industrial design, translation, and development strategies for long-acting peptide delivery

Patient-Centric Long-Acting Injectable and Implantable Platforms─An Industrial Perspective

Design and translation of injectable biomaterials

Development and approval of novel injectables: enhancing therapeutic innovations

Long-acting microneedles: a progress report of the state-of-the-art techniques

An injectable, nanostructured implant for the delivery of adenosine triphosphate: towards long-acting formulations of small, hydrophilic drugs

PLGA-based implants for sustained delivery of peptides/proteins: Current status, challenge and perspectives

Long-Acting Gel Formulations: Advancing Drug Delivery across Diverse Therapeutic Areas

Strategies for the production of long-acting therapeutics and efficient drug delivery for cancer treatment

Ultra-Long-Term Delivery of Hydrophilic Drugs Using Injectable In Situ Cross-Linked Depots

Oral Delivery of Insulin by Barbed Microneedles Actuated by Intestinal Peristalsis

Machine learning models to accelerate the design of polymeric long-acting injectables

The Future of Painless Injection: Exploring the Materials Used, Manufacturing Materials and It’s Applications in Transdermal Drug Delivery System

Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies